A combination therapy of both a potent and long-lasting ATX inhibitor along with an appropriately selective LPAR blockade, potentially incorporated as a single compound as in the case of ongoing efforts to design dual ATX-LPAR1 inhibitors [39], should provide a robust adjunct therapy that can mitigate cancer treatment failure or side effects, such as radiation-induced fibrosis in breast cancer adjuvant radiotherapy [40]. Here, ENPP2 is linked to breast carcinoma.